Over the next year, SGD Pharma intends to continue its investment into new ventures, build upon the company’s current efforts towards sustainability and expand its range of glass packaging.
Innovative technology for clinical trials is now, more than ever, necessary to deliver decentralized trials (DCT) and enable design of hybrid protocols that support trial continuity and patient-centricity.
Aigenpulse has rolled out an update to its CytoML Experiment Suite – its automated, end-to-end, machine learning solution specifically aimed at streamlining and automating cytometry analysis at scale and replacing manual gating processes.